MDWD News and Press, MediWound Ltd. From 11/04/21

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the t...

YAVNE, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced a peer-reviewed publication in the Journal of Wound Care of a...

YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at...

Mediwound Ltd (MDWD) Q2 2021 Earnings Conference Call August 10, 2021, 08:30 ET Company Participants Jeremy Feffer - LifeSci Advisors Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Kevin DeGeeter - Oppenheimer Joshua Jennings - Cowen and Company Swayampakula Ramakanth - ...

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year Positive Interim Assessment Outcome for EscharEx U.S. Phase II Clinical Study No Changes to Study Sample Size – No Safety Concerns Identified Conference call begins today at 8:30 am ET ...

YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the s...

MediWound is developing treatment alternatives in the skin and burn products, which are set to save patients both pain and money. Even so, approval processes and share price movements have been unsteady, with the company expecting a stagnant growth environment for the next few years. ...

The FDA sent MediWound a Complete Response Letter for their eschar removal treatment, NexoBrid. The FDA was not able to inspect the company’s manufacturing facilities due to pandemic travel restrictions. I believe they will be able to address the cited issues in the CRL, howeve...

Independent Data Monitoring Committee R ecommends C ontinuation of the Study with N o C hanges to Study Sample Size No Safety Concerns Identified Full Study Enrollment Expected by Year-End 2021; D ...

Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-ther...